Postoperative Residual Neuromuscular Block and Passive Smoke Exposure in Pediatric Dental Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Passive Smoke Exposure: Passive smoke exposure is defined based on parental or legal guardian report of the child's exposure to tobacco smoke in the household or other environments. No intervention is administered as part of the study
Study summary
Postoperative residual neuromuscular block (PRNB) may persist despite apparent clinical recovery from neuromuscular blockade and may increase the risk of postoperative respiratory complications. Quantitative neuromuscular monitoring is therefore important for identifying incomplete neuromuscular recovery. This prospective, single-center observational cohort study aims to determine the incidence of PRNB in pediatric patients undergoing dental procedures under general anesthesia with rocuronium and to evaluate the association between passive smoke exposure and PRNB. Children aged 2-12 years will undergo quantitative neuromuscular assessment using the TOF-Watch SX after clinical extubation and admission to the post-anesthesia care unit (PACU). PRNB will be defined as a train-of-four (TOF) ratio \<0.9. The incidence of PRNB will be determined, and its association with passive smoke exposure and perioperative clinical variables will be evaluated.
Eligibility
Primary outcome measure(s)
- Incidence of Postoperative Residual Neuromuscular Block — At admission to the post-anesthesia care unit (PACU), immediately after extubation
Percentage of participants with postoperative residual neuromuscular block (PRNB), defined as a normalized train-of-four (TOF) ratio \<0.90 measured at the adductor pollicis using TOF-Watch SX neuromuscular monitoring.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Istanbul University-Cerrahpasa, Institute of Cardiology | Istanbul | Istanbul |
More Istanbul University - Cerrahpasa trials in Turkey
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07831434 on ClinicalTrials.gov ↗ ← All trials in Turkey